Skip to main content
SpringerLink
Log in

Resectable and Borderline Resectable Pancreatic Cancer

  • Chapter
  • First Online:
Textbook of Gastrointestinal Oncology

  • 860 Accesses

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a devastating illness that takes the lives of virtually all diagnosed. The 5-year survival for patients who have undergone surgical resection with curative intent remains less than 20%. Considerable effort has thus been expended into the development of adjuncts to surgical management, including both adjuvant and neoadjuvant therapies. The importance of a complete or R0 resection has been documented in terms of its benefit on overall survival. Hence, the determination of resectability is paramount. Improved diagnostics and advancements in surgical techniques have led to the emergence of borderline resectable tumors, a spectrum of disease falling between overtly resectable and locally advanced, unresectable PDACs. Uniformly defining this patient population is essential, both to optimally care for more patients and for the development of stage-specific, novel clinical trials. A multimodal approach to patient care done in high-volume centers ensures that physicians with the most expertise will be caring for this complex patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Anonymous. Seer cancer statistics-pancreas, 2007–2013. [cited 2018]; Available from: https://seer.cancer.gov/statfacts/html/pancreas.html.

  2. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72(7):2118–23.

    Article  CAS  PubMed  Google Scholar 

  3. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66(1):56–61.

    Article  CAS  PubMed  Google Scholar 

  4. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–33.

    Article  PubMed  Google Scholar 

  5. Evans DB, Multidisciplinary Pancreatic Cancer Study G. Resectable pancreatic cancer: the role for neoadjuvant/preoperative therapy. HPB (Oxford). 2006;8(5):365–8.

    Article  Google Scholar 

  6. O’Malley ME, Boland GW, Wood BJ, Fernandez-del Castillo C, Warshaw AL, Mueller PR. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical ct. AJR Am J Roentgenol. 1999;173(6):1513–8.

    Article  PubMed  Google Scholar 

  7. Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ, de Wit LT, Verbeek PC, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg. 1994;81(11):1642–6.

    Article  CAS  PubMed  Google Scholar 

  8. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic tumor study group. Ann Surg. 1996;223(2):154–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg. 1998;85(5):611–7.

    Article  CAS  PubMed  Google Scholar 

  10. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935–49; discussion 949–950.

    Article  PubMed  Google Scholar 

  11. Ishikawa O, Ohigashi H, Imaoka S, Furukawa H, Sasaki Y, Fujita M, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg. 1992;215(3):231–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Loyer EM, David CL, Dubrow RA, Evans DB, Charnsangavej C. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section ct. Abdom Imaging. 1996;21(3):202–6.

    Article  CAS  PubMed  Google Scholar 

  13. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical ct. AJR Am J Roentgenol. 1997;168(6):1439–43.

    Article  CAS  PubMed  Google Scholar 

  14. Tran Cao HS, Balachandran A, Wang H, Nogueras-Gonzalez GM, Bailey CE, Lee JE, et al. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014;18(2):269–78; discussion 278.

    Article  PubMed  Google Scholar 

  15. Network NCC. National comprehensive cancer network (nccn) clinical practice guidelines in oncology. Pancreatic adenocarcinoma. Available from: http://www.nccn.org/professionals/physician_gls/default.asp.

  16. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.

    Article  PubMed  Google Scholar 

  17. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46; discussion 846-838.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Katz MH, Pisters PW, Lee JE, Fleming JB. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol. 2011;18(3):608–10.

    Article  PubMed  Google Scholar 

  19. Kelly KJ, Winslow E, Kooby D, Lad NL, Parikh AA, Scoggins CR, et al. Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of "borderline resectable disease"? J Gastrointest Surg. 2013;17(7):1209–17; discussion 1217.

    Article  PubMed  Google Scholar 

  20. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6(12):1301–8.

    Article  PubMed  Google Scholar 

  22. Megibow AJ, Babb JS, Hecht EM, Cho JJ, Houston C, Boruch MM, et al. Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row ct. Radiology. 2006;238(1):87–95.

    Article  PubMed  Google Scholar 

  23. Bronstein YL, Loyer EM, Kaur H, Choi H, David C, DuBrow RA, et al. Detection of small pancreatic tumors with multiphasic helical ct. AJR Am J Roentgenol. 2004;182(3):619–23.

    Article  PubMed  Google Scholar 

  24. White R, Winston C, Gonen M, D’Angelica M, Jarnagin W, Fong Y, et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg. 2008;206(3):445–50.

    Article  PubMed  Google Scholar 

  25. Borbath I, Van Beers BE, Lonneux M, Schoonbroodt D, Geubel A, Gigot JF, et al. Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. Pancreatology. 2005;5(6):553–61.

    Article  PubMed  Google Scholar 

  26. Friess H, Kleeff J, Silva JC, Sadowski C, Baer HU, Buchler MW. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg. 1998;186(6):675–82.

    Article  CAS  PubMed  Google Scholar 

  27. Walters DM, Lapar DJ, de Lange EE, Sarti M, Stokes JB, Adams RB, et al. Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011;18(10):2764–71.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Porembka MR, Hawkins WG, Linehan DC, Gao F, Ma C, Brunt EM, et al. Radiologic and intraoperative detection of need for mesenteric vein resection in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford). 2011;13(9):633–42.

    Article  Google Scholar 

  29. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Halligan S. Subspecialist radiology. Clin Radiol. 2002;57(11):982–3.

    Article  CAS  PubMed  Google Scholar 

  31. Muller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic us, ct, and mr imaging. Radiology. 1994;190(3):745–51.

    Article  CAS  PubMed  Google Scholar 

  32. Puli SR, Bechtold ML, Buxbaum JL, Eloubeidi MA. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: a meta-analysis and systematic review. Pancreas. 2013;42(1):20–6.

    Article  PubMed  Google Scholar 

  33. Adler DG, Jacobson BC, Davila RE, Hirota WK, Leighton JA, Qureshi WA, et al. Asge guideline: complications of eus. Gastrointest Endosc. 2005;61(1):8–12.

    Article  PubMed  Google Scholar 

  34. Lee ES. Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20(24):7864–77.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Raman SP, Horton KM, Fishman EK. Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J. 2012;18(6):511–22.

    Article  PubMed  Google Scholar 

  36. Miller FH, Rini NJ, Keppke AL. Mri of adenocarcinoma of the pancreas. AJR Am J Roentgenol. 2006;187(4):W365–74.

    Article  PubMed  Google Scholar 

  37. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  38. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.

    Article  CAS  PubMed  Google Scholar 

  39. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.

    Article  CAS  PubMed  Google Scholar 

  40. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865–7.

    Article  CAS  PubMed  Google Scholar 

  41. Haslam JB, Cavanaugh PJ, Stroup SL. Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer. 1973;32(6):1341–5.

    Article  CAS  PubMed  Google Scholar 

  42. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903.

    Article  CAS  PubMed  Google Scholar 

  43. Anonymous. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal tumor study group. Cancer. 1987;59(12):2006–10.

    Article  Google Scholar 

  44. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase iii trial of the eortc gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82; discussion 782-774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.

    Article  CAS  PubMed  Google Scholar 

  46. 3rd Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.

    Article  CAS  PubMed  Google Scholar 

  47. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J, Oettle H. Oettle Deutsche Krebsgesellschaft (CAO/AIO) Conko-001: final results of the randomized, prospective, multicenter phase iii trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (pc). J Clin Oncol. 2008;26(15S):LBA 4504.

    Article  Google Scholar 

  48. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26.

    Article  CAS  PubMed  Google Scholar 

  49. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.

    Article  CAS  PubMed  Google Scholar 

  50. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (espac-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.

    Article  CAS  PubMed  Google Scholar 

  51. Lawrence TS, Davis MA, Hough A, Rehemtulla A. The role of apoptosis in 2’,2’-difluoro-2’-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res. 2001;7(2):314–9.

    CAS  PubMed  Google Scholar 

  52. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized eortc-40013-22012/ffcd-9203/gercor phase ii study. J Clin Oncol. 2010;28(29):4450–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of s-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (jaspac 01). Lancet. [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2016;388(10041):248–57.

    Article  CAS  PubMed  Google Scholar 

  54. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol. 2007;25(15):1960–6.

    Article  CAS  PubMed  Google Scholar 

  55. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase iii trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22(8):1430–8.

    Article  CAS  PubMed  Google Scholar 

  56. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621–33; discussion 633-626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15(3):928–37.

    Article  CAS  PubMed  Google Scholar 

  58. Cheng TY, Sheth K, White RR, Ueno T, Hung CF, Clary BM, et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2006;13(1):66–74.

    Article  PubMed  Google Scholar 

  59. Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997;226(5):632–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase ii trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an eastern cooperative oncology group study. J Clin Oncol. 1998;16(1):317–23.

    Article  CAS  PubMed  Google Scholar 

  61. Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol. 2000;18(4):860–7.

    Article  CAS  PubMed  Google Scholar 

  62. White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8(10):758–65.

    Article  CAS  PubMed  Google Scholar 

  63. Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18(1):16–24; discussion 24-15.

    Article  PubMed  Google Scholar 

  64. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335–9.

    Article  CAS  PubMed  Google Scholar 

  65. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998;16(12):3843–50.

    Article  CAS  PubMed  Google Scholar 

  66. Yeung RS, Weese JL, Hoffman JP, Solin LJ, Paul AR, Engstrom PF, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase ii study. Cancer. 1993;72(7):2124–33.

    Article  CAS  PubMed  Google Scholar 

  67. Talamonti MS, Jr Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al. A multi-institutional phase ii trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13(2):150–8.

    Article  PubMed  Google Scholar 

  68. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496–502.

    Article  CAS  PubMed  Google Scholar 

  69. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, et al. Phase ii study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92(3):569–77.

    Article  CAS  PubMed  Google Scholar 

  70. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3487–95.

    Article  CAS  PubMed  Google Scholar 

  71. Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119(15):2692–700.

    Article  CAS  PubMed  Google Scholar 

  72. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14(7):2088–96.

    Article  PubMed  Google Scholar 

  73. Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase ii trial. Ann Surg. 2008;248(6):1014–22.

    Article  PubMed  Google Scholar 

  74. Heinrich S, Pestalozzi BC, Schafer M, Weber A, Bauerfeind P, Knuth A, et al. Prospective phase ii trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(15):2526–31.

    Article  CAS  PubMed  Google Scholar 

  75. O’Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, et al. A single-arm, nonrandomized phase ii trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260(1):142–8.

    Article  PubMed  Google Scholar 

  76. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001;5(1):27–35.

    Article  CAS  PubMed  Google Scholar 

  77. Jr Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase ii trial. J Clin Oncol. 2008;26(6):942–7.

    Article  CAS  PubMed  Google Scholar 

  78. Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195(3):318–21.

    Article  CAS  PubMed  Google Scholar 

  79. Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–27.

    Article  PubMed  Google Scholar 

  80. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516–22.

    Article  PubMed  Google Scholar 

  81. Abrams RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751–6.

    Article  PubMed  Google Scholar 

  82. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, et al. Randomized phase ii study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.

    Article  PubMed  Google Scholar 

  84. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  PubMed  Google Scholar 

  85. Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17(11):2832–8.

    Article  PubMed  Google Scholar 

  86. Katz MHG, QS SAA, Herman JM, Marsh R d W, Collisson EA, Schwartz LH, Martin RCG, Conway WC, Truty M, Kindler HL, Lowy AM, Philip PA, Bekaii-Saab TS, Cardin DB, LoConte NK, Venook AP. Preoperative modified folfirinox (mfolfirinox) followed by chemoradiation (crt) for borderline resectable (blr) pancreatic cancer (pdac): initial results from alliance trial a021101. J Clin Oncol, ASCO Annual Meeting. 2015;33(15, May 20 Supplement):4008.

    Google Scholar 

  87. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  88. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. Ann Surg. 1935;102(4):763–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Whipple AO. Observations on radical surgery for lesions of the pancreas. Surg Gynecol Obstet. 1946;82:623–31.

    CAS  PubMed  Google Scholar 

  90. Ahmad SA, Lowy AM, McIntyre BC, Matthews JB. Pancreaticoduodenectomy. J Gastrointest Surg. 2005;9(1):138–43.

    Article  PubMed  Google Scholar 

  91. de Rooij T, Lu MZ, Steen MW, Gerhards MF, Dijkgraaf MG, Busch OR, et al. Minimally invasive versus open pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and registry studies. Ann Surg. 2016;264(2):257–67.

    Article  PubMed  Google Scholar 

  92. Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, Fisher S, Vinuela EF, Kingham TP, et al. Minimally-invasive vs open pancreaticoduodenectomy: systematic review and meta-analysis. J Am Coll Surg. 2014;218(1):129–39.

    Article  PubMed  Google Scholar 

  93. Traverso LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet. 1978;146(6):959–62.

    CAS  PubMed  Google Scholar 

  94. Traverso LW, Jr Longmire WP. Preservation of the pylorus in pancreaticoduodenectomy a follow-up evaluation. Ann Surg. 1980;192(3):306–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC, Greve JW, et al. Pylorus preserving pancreaticoduodenectomy versus standard whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg. 2004;240(5):738–45.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Seiler CA, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical whipple resection-long term results. Br J Surg. 2005;92(5):547–56.

    Article  CAS  PubMed  Google Scholar 

  97. Diener MK, Heukaufer C, Schwarzer G, Seiler CM, Antes G, Buchler M, et al. Pancreaticoduodenectomy (classic whipple) versus pylorus-preserving pancreaticoduodenectomy (pp whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev. 2008;(2):Cd006053.

    Google Scholar 

  98. Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73(2):307–20.

    CAS  PubMed  Google Scholar 

  99. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg. 1984;199(4):418–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg. 1988;208(2):215–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Manabe T, Ohshio G, Baba N, Miyashita T, Asano N, Tamura K, et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer. 1989;64(5):1132–7.

    Article  CAS  PubMed  Google Scholar 

  102. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy study group. Ann Surg. 1998;228(4):508–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999;229(5):613–22; discussion 622-614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236(3):355–66; discussion 366-358.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: Update on 5-year survival. J Gastrointest Surg. 2005;9(9):1191–204; discussion 1204-1196.

    Article  PubMed  Google Scholar 

  106. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618–28; discussion 628-630.

    Article  PubMed  Google Scholar 

  107. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140(6):584–9; discussion 589-591.

    Article  PubMed  Google Scholar 

  108. Evans DB, Farnell MB, Lillemoe KD, Jr Vollmer C, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1736–44.

    Article  PubMed  Google Scholar 

  109. Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014;218(3):401–11.

    Article  PubMed  Google Scholar 

  110. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):884–91.

    Article  PubMed  Google Scholar 

  111. Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg. 2010;14(9):1442–52.

    Article  PubMed  Google Scholar 

  112. Liles JS, Katz MH. Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma. Expert Rev Anticancer Ther. 2014;14(8):919–29.

    Article  CAS  PubMed  Google Scholar 

  113. Castleberry AW, White RR, De La Fuente SG, Clary BM, 3rd Blazer DG, McCann RL, et al. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the american college of surgeons national surgical quality improvement program database. Ann Surg Oncol. 2012;19(13):4068–77.

    Article  PubMed  Google Scholar 

  114. Tseng JF. Proceed with caution: vascular resection at pancreaticoduodenectomy. Ann Surg Oncol. 2012;19(13):4001–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, University of Cincinnati Medical Center, Cincinnati, OH, USA

    Megan A. Stevenson & Sameer H. Patel

  2. Department of Surgery, Division of Surgical Oncology, Pancreas Disease Center, University of Cincinnati Cancer Institute, University of Cincinnati Medical Center, Cincinnati, OH, USA

    Syed A. Ahmad

Authors
  1. Megan A. Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sameer H. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Syed A. Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed A. Ahmad .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Philip A. Philip

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Stevenson, M.A., Patel, S.H., Ahmad, S.A. (2019). Resectable and Borderline Resectable Pancreatic Cancer. In: Yalcin, S., Philip, P. (eds) Textbook of Gastrointestinal Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-18890-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18890-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18888-7

  • Online ISBN: 978-3-030-18890-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation